Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

ClinicalTrials.gov ID: NCT00036465

Public ClinicalTrials.gov record NCT00036465. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Controlled, Pilot Study of Antiretroviral Switch at Lower Versus Higher HIV-1 RNA Levels in Subjects Experiencing Virologic Relapse on a Current HAART Regimen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will look at people who have been taking anti-HIV drugs but still have detectable levels of HIV. The purpose of the study is to find out what happens in those people who change anti-HIV drugs when their viral load reaches 200 copies compared to those who change anti-HIV drugs when their viral load reaches 10,000 copies. This study will also look at drug resistance (how well HIV responds to drugs), viral fitness (how well drug-resistant HIV copies itself), and immunologic reconstitution (how well the immune system recognizes various infections, including HIV). Many patients experience virologic relapse (increase in viral load after sustained viral load suppression) within 1 to 2 years of taking anti-HIV drugs. The approach to treatment for patients who experience virologic relapse while on a highly active antiretroviral therapy (HAART) has not been defined. Current guidelines recommend switching to a new treatment regimen as soon as possible to prevent HIV from becoming even more resistant to anti-HIV drugs. However, there is evidence that patients can benefit from staying on the same HAART drugs, even after virologic relapse. This study wants to find what happens when drugs are changed immediately after virologic relapse (when the viral load is lower) compared to what happens if drugs are changed only after a delay (when the viral load is higher).

Study identification

NCT ID
NCT00036465
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
60 participants

Conditions and interventions

Conditions

Interventions

Behavioral

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Aug 31, 2005
Last update posted
Jul 28, 2013

Ends 2005

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Willow Clinic Menlo Park California 94025 —
San Mateo AIDS Program / Stanford Univ Stanford California 94305-5107 —
Stanford Univ Med Ctr Stanford California 94305-5107 —
Harbor General/UCLA Torrance California 90502-2052 —
Univ of Colorado Health Sciences Ctr Denver Colorado 80262 —
Univ of Miami School of Medicine Miami Florida 331361013 —
Univ of Hawaii Honolulu Hawaii 96816 —
Northwestern Univ Chicago Illinois 60611 —
Rush Presbyterian - Saint Luke's Med Ctr Chicago Illinois 60612 —
The CORE Ctr Chicago Illinois 60612 —
Harvard (Masschusetts General Hosp) Boston Massachusetts 02114 —
Brigham and Womens Hosp Boston Massachusetts 02215 —
Bellevue Hosp / New York Univ Med Ctr New York New York 10016 —
Univ of North Carolina Chapel Hill North Carolina 27599-7215 —
Duke Univ Med Ctr Durham North Carolina 27710 —
Univ of Cincinnati Cincinnati Ohio 452670405 —
Univ of Pittsburgh Pittsburgh Pennsylvania 15213 —
Brown Univ / Miriam Hosp Providence Rhode Island 02906 —
Miriam Hosp / Brown Univ Providence Rhode Island 02906 —
Comprehensive Care Clinic / Vanderbilt Univ Med Ctr Nashville Tennessee 37203 —
Univ of Texas, Southwestern Med Ctr of Dallas Dallas Texas 75390 —
Univ of Texas Galveston Galveston Texas 775550435 —
Univ of Washington Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00036465, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 28, 2013 · Synced Sep 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00036465 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →